Dichotomous effects of exposure to bivalirudin in patients undergoing percutaneous coronary intervention on protease-activated receptor-mediated platelet activation

[1]  F. Harrell,et al.  Racial Differences in Resistance to P2Y12 Receptor Antagonists in Type 2 Diabetic Subjects , 2014, The Journal of Pharmacology and Experimental Therapeutics.

[2]  Munich,et al.  Prognostic value of a high on-clopidogrel treatment platelet reactivity in bivalirudin versus abciximab treated non-ST-segment elevation myocardial infarction patients. ISAR-REACT 4 (Intracoronary Stenting and Antithrombotic Regimen: Rapid Early Action for Coronary Treatment-4) platelet substudy. , 2012, Journal of the American College of Cardiology.

[3]  Marc P. Bonaca,et al.  Vorapaxar in the secondary prevention of atherothrombotic events. , 2012, The New England journal of medicine.

[4]  Giuseppe Ambrosio,et al.  Thrombin-receptor antagonist vorapaxar in acute coronary syndromes. , 2012, The New England journal of medicine.

[5]  Jörg Hausleiter,et al.  Abciximab and heparin versus bivalirudin for non-ST-elevation myocardial infarction. , 2011, The New England journal of medicine.

[6]  A. Weintraub,et al.  Bivalirudin Is a Dual Inhibitor of Thrombin and Collagen-Dependent Platelet Activation in Patients Undergoing Percutaneous Coronary Intervention , 2011, Circulation. Cardiovascular interventions.

[7]  Deepak L. Bhatt,et al.  Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate. , 2010, Journal of the American College of Cardiology.

[8]  H. Hamm,et al.  Irreversible Platelet Activation Requires Protease-Activated Receptor 1-Mediated Signaling to Phosphatidylinositol Phosphates , 2009, Molecular Pharmacology.

[9]  A. Kaider,et al.  Regulation of PAR-1 in patients undergoing percutaneous coronary intervention: effects of unfractionated heparin and bivalirudin. , 2009, European heart journal.

[10]  S. Steinhubl,et al.  G-Protein–Coupled Receptors as Signaling Targets for Antiplatelet Therapy , 2009, Arteriosclerosis, thrombosis, and vascular biology.

[11]  K. Mahaffey,et al.  Safety and tolerability of SCH 530348 in patients undergoing non-urgent percutaneous coronary intervention: a randomised, double-blind, placebo-controlled phase II study , 2009, The Lancet.

[12]  H. Hamm,et al.  Erratum: Protease-activated receptors differentially regulate human platelet activation through a phosphatidic acid-dependent pathway (Molecular Pharmacology (2007) 71 (686-694)) , 2009 .

[13]  M. Nieman.  Protease-activated receptor 4 uses anionic residues to interact with alpha-thrombin in the absence or presence of protease-activated receptor 1. , 2008, Biochemistry.

[14]  B. Gersh,et al.  Bivalirudin during primary PCI in acute myocardial infarction. , 2008, The New England journal of medicine.

[15]  G. Stone,et al.  Safety and efficacy of bivalirudin monotherapy in patients with diabetes mellitus and acute coronary syndromes: a report from the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) trial. , 2008, Journal of the American College of Cardiology.

[16]  H. Hamm,et al.  Protease-Activated Receptors Differentially Regulate Human Platelet Activation through a Phosphatidic Acid-Dependent Pathway , 2007, Molecular Pharmacology.

[17]  H. Hamm,et al.  PAR4, but Not PAR1, Signals Human Platelet Aggregation via Ca2+ Mobilization and Synergistic P2Y12 Receptor Activation* , 2006, Journal of Biological Chemistry.

[18]  A. Leger,et al.  Protease-Activated Receptors in Cardiovascular Diseases , 2006, Circulation.

[19]  B. Sobel,et al.  Greater inhibitory effects of bivalirudin compared with unfractionated heparin plus eptifibitide on thrombin-induced platelet activation , 2006, Coronary artery disease.

[20]  C. Derian,et al.  Blocking the Protease-Activated Receptor 1-4 Heterodimer in Platelet-Mediated Thrombosis , 2006, Circulation.

[21]  H. Dauerman,et al.  Increased expression of platelet P-selectin and formation of platelet-leukocyte aggregates in blood from patients treated with unfractionated heparin plus eptifibatide compared with bivalirudin. , 2006, Thrombosis research.

[22]  S. Coughlin,et al.  Protease‐activated receptors in hemostasis, thrombosis and vascular biology , 2005, Journal of thrombosis and haemostasis : JTH.

[23]  T. Fischer,et al.  Rap1b is required for normal platelet function and hemostasis in mice. , 2005, The Journal of clinical investigation.

[24]  Hisao Ikeda,et al.  Platelet P-selectin plays an important role in arterial thrombogenesis by forming large stable platelet-leukocyte aggregates. , 2002, Journal of the American College of Cardiology.

[25]  P. Thiagarajan,et al.  P-selectin in arterial thrombosis , 2004, Zeitschrift für Kardiologie.

[26]  A. Graybiel,et al.  CalDAG-GEFI integrates signaling for platelet aggregation and thrombus formation , 2004, Nature Medicine.

[27]  E. Topol,et al.  Long-term efficacy of bivalirudin and provisional glycoprotein IIb/IIIa blockade vs heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary revascularization: REPLACE-2 randomized trial. , 2004, JAMA.

[28]  M. Lagarde,et al.  Diabetic patients without vascular complications display enhanced basal platelet activation and decreased antioxidant status. , 2004, Diabetes.

[29]  B. Sobel,et al.  Decreased Platelet Reactivity in Blood Anticoagulated with Bivalirudin or Enoxaparin Compared with Unfractionated Heparin: Implications for Coronary Intervention , 2002, Journal of Thrombosis and Thrombolysis.

[30]  Gregory Y H Lip,et al.  The adhesion molecule P-selectin and cardiovascular disease. , 2003, European heart journal.

[31]  B. Isermann,et al.  The thrombomodulin–protein C system is essential for the maintenance of pregnancy , 2003, Nature Medicine.

[32]  José A Fernández,et al.  Activated protein C blocks p53-mediated apoptosis in ischemic human brain endothelium and is neuroprotective , 2003, Nature Medicine.

[33]  S. Yusuf,et al.  The evolving role of direct thrombin inhibitors in acute coronary syndromes. , 2003, Journal of the American College of Cardiology.

[34]  M. Runge,et al.  New tricks for old dogs: nonthrombotic effects of thrombin in vessel wall biology. , 2001, Circulation research.

[35]  J. D. Hellums,et al.  A New Role for P-Selectin in Shear-Induced Platelet Aggregation , 2000, Circulation.

[36]  S. Coughlin,et al.  Thrombin signalling and protease-activated receptors , 2000, Nature.

[37]  P Théroux,et al.  Platelet activation with unfractionated heparin at therapeutic concentrations and comparisons with a low-molecular-weight heparin and with a direct thrombin inhibitor. , 1998, Circulation.

[38]  G. Jamieson.  Pathophysiology of Platelet Thrombin Receptors , 1997, Thrombosis and Haemostasis.

[39]  C. Esmon,et al.  Antithrombotic effects of thrombin-induced activation of endogenous protein C in primates. , 1993, The Journal of clinical investigation.

[40]  C. Gennings,et al.  Synergistic inhibition of platelet aggregation by fibrinogen-related peptides. , 1990, Circulation research.

[41]  J. Hoxie,et al.  Detection of activated platelets in whole blood using activation-dependent monoclonal antibodies and flow cytometry. , 1987, Blood.